ScholarWorks@Korea University College of Medicine: Kim, Seung Hyun

Detailed Information

Kim, Seung Hyun (김승현)

Guro Hospital (Department of Psychiatry, Guro Hospital)

Research Area

Tel 02-2626-3162
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

schizophrenia:19||Schizophrenia:10||polymorphism:9||Depression:6||Adherence:5||Tardive dyskinesia:4||Polymorphism:4||스트레스:4||informed consent:3||tardive dyskinesia:3||Insight:3||Alzheimer's disease:3||조현병:3||ROC analysis:3||restless legs syndrome:3||Bipolar disorder:3||Medication Event Monitoring System:3||remission:2||Pharmacotherapy:2||outcome:2||Psychosis:2||retrosplenial cortex:2||risperidone:2||panic disorder:2||perceived coercion:2||Alzheimer disease:2||PHQ9:2||cognitive function:2||consent competency to treatment:2||mental health:2||mental illness:2||antipsychotics:2||anxiety disorder:2||Firstepisode psychosis:2||Elderly:2||depression:2||Reliability:2||negative symptoms:2||정신분열병:2||brainderived neurotrophic factor:2||기억:2||obesity:2||Economic problem:1||Electroconvulsive therapy:1||Embitterment:1||Emotional support:1||Exercise:1||Factors:1||Family:1||Fatigue:1||Females:1||First episode psychosis:1||Full remission:1||Gprotein:1||Gamblers anonymous:1||Gambling disorder:1||Gambling disorder·Screening·Diagnosis·Assessment·Pharmacotherapy· Psychosocial treatment·Cognitivebehavioral therapy.:1||General Population:1||Happiness:1||Haptic:1||Health:1||Health Insurance Review and Assessment Service Data:1||Informed consent:1||Interleukin10:1||Interpersonal trust:1||Irbesartan:1||KEPS:1||KMAP· Schizophrenia· Pharmacotherapy·:1||KMAP·정신분열병·약물치료·알고리듬.:1||Korea:1||Korea Assessment Tool of Competency:1||Korea National Health and Nutrition Examination Survey:1||Latelife depression:1||MK801:1||MK801:1||Major depressive disorder· Psychotic features· Antidepresants· Antipsychotics· ECT.:1||Manganese superoxide dismutase:1||Mania:1||Medication event monitoring system:1||Memory:1||Mental illness:1||Mirtazapine.:1||NMethylDAspartate:1||NMethylDAspartate 수용체:1||NMDA antagonists:1||NMDA 수용체:1||Naltrexone:1||Negative Symptoms:1||Negative schema:1||Negative symptom:1||Neuroendocrinology:1||Neuropsychological function:1||Opioid receptor antagonist:1||Oxidative stress:1||P300:1||PANSS:1||PAWR:1||PBMC:1||PHQ15:1||PTED:1||Panic disorder:1||Paternalism:1||Pathological worry:1||Perceived stress:1||Perceived stress scale:1||Personal and social functioning:1||Pharmacogenomics· Antidepressants· Depresion· Serotonin transporter.:1||Polydipsia:1||Polyenvironmental risk factor:1||Positron emission tomography:1||Postmenopause:1||Predicting factor:1||Prediction:1||Pregnancy:1||Premenopause:1||Prevalence of Depression:1||Problem focused coping skill:1||Psychopathology:1||Psychosocial treatment:1||ROC:1||RTPCR:1||Recentonset psychosis:1||Reciprocity:1||Recovery:1||Relapse:1||Remission:1||Rumination:1||SPAQ:1||SWNK:1||Schizophrenia & Frontal lobes:1||Schizophrenia and psychotic disorder:1||Schizophrenia subtype:1||Schizophrenia· Bipolar disorder· Korean medication algorithm project for major psychiatric disorders.:1||Schizophrenia· ECT· Child.:1||Schizophrenia· Korean medication algorithm· Feasibility test· Effectiveness.:1||Schizophrenia· Korean medication algorithm· Feasibility· Therapeutic environment.:1||Schizophrenia· Pharmacotherapy· Algorithm· Korean Medication Algorithm Project for Major Psychiatric Disorders.:1||Seizure threshold:1||Skin:1||Social capital:1||Social support:1||Stem Sense:1||Stress:1||Stress coping skill:1||Subjective wellbeing:1||Suicidality:1||Switching:1||Symptom:1||Symptoms:1||TCI:1||Tactile:1||Trauma · Psychosis · Psychotic symptoms · Social and occupational functioning.:1||Treatment response:1||Triglyceride:1||Validity:1||Validity.:1||Valproate:1||Weight gain:1||Worry scale:1||Ziprasidone:1||adolescent:1||adult palliative care:1||adult psychiatry:1||amygdala:1||amyloid:1||angerrelated behavior:1||antidepressant induced mania:1||anxiety:1||assessment:1||attention deficit disorder with hyperactivity:1||attitude:1||atypical antipsychotics:1||biomarkers:1||bipolar disorder:1||blonanserin:1||bupropion:1||catecholOmethyltransferase gene:1||clinical staging:1||clinical trial:1||coercion:1||coercion in psychiatric care:1||cognitive dysfunction:1||cohort:1||cytochrome P450 2D6 (CYP2D6):1||cytochrome P450 3A5 (CYP3A5):1||cytokine:1||data collection:1||default mode network:1||dehydroepiandrosterone sulfate:1||delirium:1||dementia:1||depressive diorder:1||depressive disorder:1||diagnostic stability:1||dissociative anesthetics:1||dopamine D4 receptor:1||dopamine receptor genes, polymorphism:1||dopamine transporter:1||early psychosis:1||early stage:1||efficacy:1||elder:1||estrogen:1||facial affect recognition:1||firstepisode psychosis:1||free testosterone:1||frontoparietal network:1||genderspecific:1||gene polymorphisms:1||genegene interaction:1||genes:1||haloperidol:1||health policy:1||hematocrit:1||hemodialysis:1||heterosis:1||heterozygote advantage:1||hormone replacement therapy:1||insomnia:1||interoceptive exposure:1||ketamine:1||latelife depression:1||leptin gene:1||longacting injection risperidone:1||major depression:1||memory:1||menopause:1||menstruation:1||mental health service:1||methylphenidate:1||microdialysis:1||mirtazapine:1||moclobemide:1||monoamine A and B genes:1||monoamine oxidase a gene:1||monoamine oxidaseA:1||mood disorder:1||nefazodone:1||network analysis:1||neurocognitive function:1||neurodegeneration:1||neurotoxicity:1||nicotine dependence:1||norepinephrine transporter:1||novelty seeking:1||olanzapine:1||overweight:1||paternalism:1||perceived functioning:1||persistence:1||personality:1||pharmacogenetics:1||pharmacological treatment:1||physiological responses:1||polymorphisms:1||positron emission tomography:1||posterior cingulate:1||prediction:1||predictor:1||premenstrual syndrome:1||prolactin:1||psychiatric disorders:1||psychiatric symptom:1||psychosis:1||psychotic disorder NOS:1||psychotic symptom:1||psychotic symptoms:1||public health:1||quality of life:1||rats:1||recurrence:1||relapse:1||relaxation:1||research domain criteria (RDoC):1||restingstate functional connectivity:1||retrospective cohort study:1||rodents:1||seasonality:1||selective serotonin reuptake inhibitor:1||severity:1||sexual side effect:1||somatoform disorder:1||suicidal ideation:1||suicide:1||survey:1||testosterone:1||tolerability:1||topiramate:1||treatment response:1||virtual reality:1||waist circumference:1||weight gain:1||weight loss:1||wellbeing:1||zonisamide:1||개인적 사회적 기능상태:1||걱정 척도·병적인 걱정·신뢰도·타당도.:1||경피에스트라디올:1||계절성:1||고지된 동의:1||광치료:1||기분부전장애:1||노인정신의학 치매 기억력장애:1||노화:1||다음증:1||도박장애·선별·진단·평가·약물치료·정신사회 치료·인지행동치료.:1||동의:1||렙틴:1||리스페리돈:1||문제 중심적 대처 방식:1||병식:1||불안:1||비만:1||사회적 지지:1||섭식장애:1||수면:1||스트레스 대처 방식:1||스트레스 자각척도:1||스트레스 지각 정도:1||시상하부:1||신뢰도:1||약물 순응도·알츠하이머 병·치매:1||약물유전체학·항우울제·기분 장애·세로토닌.:1||양극성 장애·기능 상태·수면·사회적 지지· 우울 증상.:1||예측 인자:1||우울:1||우울 감:1||우울증:1||우울증상:1||운동:1||월경전불쾌기분장애:1||음성증상:1||인격:1||인지 기능.:1||자살:1||정신병리:1||정신병적 우울증·항우울제·항정신병약물·
전기경련치료.:1||정신분열병 흡연 도파민 D2 수용체 유전자:1||정신분열병·양극성 장애·주요 정신질환의 약물치료에 대한 한국형 알고리듬 개발.:1||정신분열병·전기경련요법·소아.:1||정신분열병·한국형 약물치료 알고리듬·임상 적용 연구·치료환경.:1||정신분열병·한국형 약물치료 알고리듬·임상적용 연구·치료효과.:1||정신장애인:1||정신질환 약물치료:1||치료동의능력:1||콜레스테롤:1||타당도:1||폐경기여성:1||폐경전기·폐경후기·우울증·Mirtazapine.:1||피로:1||학습:1||한국판 양성 및 음성증후군 척도(Positive and Negative Syndrome Scale):1||항우울제:1||9hydroxyrisperidone:1||항우울제 약물유전체학:1||Abnormal involuntary movements:1||Alzheimer’s disease:1||Amitriptyline:1||Amyloid:1||Antenatal depression:1||Anticonvulsants:1||Antidepressants:1||Antipsychotics:1||Anxiety:1||Association:1||Attentiondeficit hyperactivity disorder:1||Attitude:1||Biological marker:1||Bipolar disorder·Depression·Function·Sleep·Social support:1||Bone density:1||Bone metabolism:1||Borna disease virus:1||Brainderived neurotrophic factor:1||CRF 수용체:1||Cognitive behavioral therapy:1||Cognitive dysfunction:1||Cognitive function:1||Cohort:1||Competency to consent:1||Compliance:1||Dcycloserine:1||DRD2 gene:1||DRD4:1||DSM5:1||Definition:1||Dehydroepiandrosterone sulfate:1||Dementia:1||Depressive disorder:1||Depressive mood:1||Depressive symptom:1||Differential diagnosis:1||Dimensions of psychosis:1||Dopamine receptor:1||Drug adherence:1||Drug monitoring:1||Early intervention:1||

STATISTICS: Total View :12,803,125; Today View :11,979

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE